Get the Stockscreener App
0.00
100.00%
-58.02
After Hours:
58.02
58.02
+
Rapt Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$58.02
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.68B
Revenue:
$3.25M
Net Income/Loss:
$-105.64M
P/E Ratio:
0.00
EPS:
-10.5107
Net Cash Flow:
$-86.66M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$58.02
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
0.00 | 1.68B | 3.25M | -105.64M | -86.66M | -10.51 |
VRTX
Vertex Pharmaceuticals Inc
|
473.09 | 119.94B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
651.91 | 68.27B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.60 | 53.28B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.75 | 38.91B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
268.74 | 35.65B | 4.29B | 577.22M | 641.34M | 4.2086 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-20-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-26-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
RAPT Therapeutics outlines its immunology pipeline as investors weigh long-term prospects - Ad Hoc News
RAPT Therapeutics Inc (RAPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RAPT Therapeutics Inc (RAPT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RAPT Therapeutics Inc (RAPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RAPT Therapeutics Inc (RAPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RAPT Therapeutics Inc (RAPT) Institutional Confidence - TradingKey
RAPT Therapeutics Inc (RAPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RAPT Therapeutics Inc (RAPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RAPT Therapeutics Inc (RAPT) Valuation: PE, PB & Fair Value Analysis - TradingKey
RAPT Therapeutics Inc (RAPT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TD Cowen initiates coverage of RAPT Therapeutics (RAPT) with buy recommendation - MSN
RAPT Therapeutics prices equity offering at $30 per share - MSN
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside - TipRanks
OrbiMed files Amendment to 13G, reports 0 RAPT shares (NASDAQ: RAPT) - Stock Titan
RTW Investments amends Schedule 13G/A for RAPT (NASDAQ: RAPT) - Stock Titan
RAPT Therapeutics stock (US74933X1090): Biotech innovator in immunology - AD HOC NEWS
TradingKey - TradingKey
Piper Sandler initiated coverage on RAPT Therapeutics with a new price target - Quantisnow
RAPT Therapeutics (RAPT) Investor Update Summary - Quartr
RAPT Price Today: RAPT Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
RAPT Therapeutics (RAPT) Wells Fargo 20th Annual Healthcare Conference 2025 summary - Quartr
RAPT Therapeutics (RAPT) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
RAPT Therapeutics (RAPT) Study Result Summary - Quartr
RAPT Therapeutics (RAPT) Stifel Virtual Immunology and Inflammation Forum Summary - Quartr
RAPT Therapeutics (RAPT) Leerink’s Global Healthcare Conference 2025 Summary - Quartr
RAPT Therapeutics (RAPT) Proxy Filing Summary - Quartr
RAPT Therapeutics (RAPT) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary - Quartr
RAPT Therapeutics (RAPT) price target decreased by 12.94% to 54.97 - MSN
Targets Report: Is RAPT Therapeutics Inc stock influenced by commodity prices2026 Highlights & Weekly High Return Opportunities - baoquankhu1.vn
Rate Cut: Can RAPT Therapeutics Inc deliver alphaQuarterly Investment Review & Verified Swing Trading Watchlist - baoquankhu1.vn
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why - MSN
Trade Recap: Can RAPT Therapeutics Inc deliver alpha2026 News Drivers & AI Forecasted Stock Moves - baoquankhu1.vn
Smart Money: Is RAPT Therapeutics Inc a speculative investment2026 Biggest Moves & Technical Entry and Exit Tips - baoquankhu1.vn
RAPT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Fed Impact: Can RAPT Therapeutics Inc deliver alpha2026 Market Outlook & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Rapt Therapeutics synthesizes new TNF-α modulators - BioWorld News
Performance Recap: Can RAPT Therapeutics Inc benefit from deglobalization2026 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Barclays Maintains RAPT Therapeutics (RAPT) Overweight Recommendation - msn.com
Aug Weekly: Is RAPT Therapeutics Inc a speculative investment2026 Price Action Summary & Short-Term High Return Strategies - baoquankhu1.vn
If You Invested $1,000 in Rapt Therapeutics, Inc. (RAPT) - Stock Titan
This Biotech Was Quietly Bought Before a $58 Per Share Takeout - AOL.com
[15-12G] RAPT Therapeutics, In... - Stock Titan
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share - AOL.com
This investor accumulated a $56 million stake in RAPT during the previous quarter. The company has now been bought out at $58 per share. - Bitget
Rapt Therapeutics Receives $48.44 Average Target Price from Analysts - National Today
Insider Sell: What analysts say about RAPT Therapeutics Inc. stockRate Cut & Expert Verified Stock Movement Alerts - baoquankhu1.vn
GSK to buy Rapt Therapeutics in deal valued at $2.2B - MSN
RAPT SEC FilingsRapt Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Rapt Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
GSK reached out to buyout target's big shareholder before talking to senior leadersSan Francisco Business Times - The Business Journals
RAPT (RAPT) director equity awards cashed out in $58-per-share GSK deal - Stock Titan
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):